Loading
A phase 2 trial of Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by Hutchmed, active and no longer recruiting.
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL is a phase 2 interventional study registered as NCT06601504 by Hutchmed, with 61 participants enrolled, started 2024-11-05 and due to reach its primary completion in 2026-05-12. Interventions recorded: HMPL-760 planned dose 1, R-GemOx, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2. Conditions listed: Relapsed/Refractory Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rituximab, Diffuse large B-cell lymphoma.
Shares Hutchmed, Diffuse large B-cell lymphoma.
Shares Hutchmed, Diffuse large B-cell lymphoma.
Shares Hutchmed, Gemcitabine.
Shares Rituximab, Diffuse large B-cell lymphoma.
Shares Rituximab, Gemcitabine, Diffuse large B-cell lymphoma.
Shares Rituximab, Diffuse large B-cell lymphoma.
Shares Rituximab, Gemcitabine, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/